IN THE CLAIMS

Please amend claims 1-3, 16, 58-60, 128, and 145 as set forth herein, and cancel claims 4-11, 30-44, 61-73, 98-101, 104-107, 110-113, 116-119, 122-125, 133-141, 149-151, 153-158, 160-162, and 164-177 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) ~~A unit dosage form comprising a sealed vial containing a~~ sufficient quantity of **cremophor-free** taxane to provide for administration to a **human** subject a total dose of taxane in the range of about 30 mg/m^2 to about 1000 mg/m^2 over an administration period no greater than about 3 hours**, wherein the cycle time between administrations of said total dose is less than about three weeks**.

2. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about ~~80~~ **50** mg/m^2 to about 700 mg/m^2.

3. (Currently Amended) A unit dosage form according to claim 1, wherein said total dose is in the range of about ~~50~~ **175** mg/m^2 to about ~~800~~ **300** mg/m^2.

4-11. (Cancelled)

12. (Original) A unit dosage form according to claim 1, wherein said taxane is administered locally.

13. (Original) A unit dosage form according to claim 1, wherein said taxane is administered systemically.

14. (Original) A unit dosage form according to claim 1, wherein said taxane is in a non-aqueous formulation.

15. (Original) A unit dosage form according to claim 1, wherein said taxane is docetaxel.

16. (Currently Amended) A unit dosage form according to claim 1, wherein said taxane **is** a paclitaxel analog.

17-57. (Cancelled)

58. (Currently Amended) A unit dosage form comprising a sealed vial containing a sufficient quantity of **cremophor-free** taxane to provide for administration to a **human** subject a total dose of taxane in the range of about ~~30 mg/m^2 to about 1000 mg/m^2, wherein said sealed vial comprises in the range of about~~ 4 mg to about 822 mg ~~of said taxane~~ **over an administration period of no greater than 3 weeks, wherein the cycle time between administrations of said total dose is less than about three weeks**.

C' cont

59. (Currently Amended) A unit dosage form according to claim 58, wherein said ~~sealed vial~~ **total dose** comprises in the range of about 4 **30** mg to about ~~13~~ **700** mg of said taxane.

60. (Currently Amended) A unit dosage form according to claim 58, wherein said ~~sealed vial~~ **total dose** comprises in the range of about ~~13~~ **100** mg to about ~~30~~ **400** mg of said taxane.

61-73 (Cancelled)

74. (Original) A unit dosage form according to claim 58, wherein said taxane is administered locally.

75. (Original) A unit dosage form according to claim 58, wherein said taxane is administered systemically.

76. (Original) A unit dosage form according to claim 58, wherein said taxane is in a non-aqueous formulation.

77. (Original) A unit dosage form according to claim 58, wherein said taxane is docetaxel.

78. (Original) A unit dosage form according to claim 58, wherein said taxane is a paclitaxel analog.

79-127. (Cancelled)

128. (Currently Amended) A **cremophor-free** taxane containing formulation contained within a sealed vial suitable for the delivery **to a human subject** of a total dose of taxane in the range of about 30 mg/m^2 to about 1000 mg/m^2, with an administration period of no greater than about 3 hours, **wherein the cycle time between administrations of said total dose is less than about three weeks**.

C1 cont

129. (Original) A formulation according to claim 128, wherein said total dose of taxane is in the range of about 80 mg/m^2 to about 700 mg/m^2.

130. (Previously Amended) A formulation according to claim 128, wherein said taxane is docetaxel.

131. (Original) A formulation according to claim 128, wherein said taxane is a paclitaxel analog.

132-144. (Cancelled)

145. (Currently Amended) A method for administration of **cremophor-free** taxane to a **human** subject in need thereof, said method comprising administering in the range of about 30 mg/m^2 to about 1000 mg/m^2 of said taxane to said subject in a pharmaceutically acceptable formulation contained within a sealed vial with a treatment cycle no greater than about 3 weeks, **wherein said administration period is no greater than about 3 hours**.

146. (Previously Amended) A method according to claim 145, wherein said taxane is docetaxel.

Cancel

147. (Original) A method according to claim 145, wherein said taxane is a paclitaxel analog.

148-177. (Cancelled)